Medical device company Kypha has raised $2.1 million in a debt offering to further it’s work in managing inflammation. With just one drop of blood, Kypha’s test works much like a diabetes test. Within just a few minutes, the test assigns a numeric value to indicate a potential condition.
At the point of care, physicians using this test would be able to make more effective decisions, especially with those suffering from diseases like Lupus, where inflammation is a mandatory thing to monitor.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Kypha has previously raised $6 million for development along with $1.5 million in grants. BioGenerator has been a prominent investor in the company, along with Arsenal Capital Management, and Serra Ventures from Champaign, Illinois; Saint Louis University’s Billiken Angels Network; St. Louis Arch Angels; and Holton Capital Group.
